Hyperlipidaemia News

  • 12 February 2019
    What explains the cardiovascular outcomes benefit with a statin or a PCSK9 inhibitor? Do effects on LDL cholesterol, as well as lipids beyond LDL cholesterol differ? A metabolite profiling study provides new insights. Treatment with statin monotherapy or as add-on to a PCSK9 inhibitor has been shown to significantly reduce major adverse...
  • 12 February 2019
    A new meta-analysis lends further support that PCSK9 inhibition reduces nonfatal major adverse cardiovascular events (MACE). However, the jury is still out regarding effects on mortality. Randomized controlled trials of at least 6 months duration were identified from searching CENTRAL, Embase, MedLine and the grey literature to November 7, 2018....
  • 17 December 2018
    Coronary artery calcium (CAC) score may have a role in stratifying short-term risk in patients with familial hypercholesterolaemia (FH, inherited high cholesterol), according to a new study. The authors suggest that this noninvasive approach may have value in targeting treatment with a PCSK9 inhibitor to those patients at highest risk. Individuals...
  • 17 December 2018
    PCSK9 Forum Editors Professor Gerald Watts (University of Western Australia, Perth. Australia) and Professor Derick Raal (University of the Witwatersrand, Johannesburg, South Africa) give their view. As a result of life-long exposure to high LDL cholesterol levels, individuals with familial hypercholesterolaemia (FH, inherited high cholesterol)...
  • 17 December 2018
    Coronary artery calcium (CAC) score may have a role in stratifying short-term risk in patients with familial hypercholesterolaemia (FH, inherited high cholesterol), according to a new study. The authors suggest that this noninvasive approach may have value in targeting treatment with a PCSK9 inhibitor to those patients at highest risk. Individuals...
  • 17 December 2018
    Professor Anthony Wierzbicki (Guys and St. Thomas’ Hospital, London UK): A view on the AHA/ACC 2018 Cholesterol Guidelines  The recent update to the AHA/ACA 2018 Cholesterol Guidelines has created much debate. Here, PCSK9 Forum Editor Professor Anthony Wierzbicki gives his view on one of the positive points of the guidelines. See related reports...
  • 17 December 2018
    Professor Raul Santos (Hospital Israelita Albert Einstein and University of São Paulo, Brazil): Is coronary artery calcium a tool for stratifying risk in familial hypercholesterolaemia?  Professor Raul Santos discusses this pertinent question in the light of results from a recent cohort study in more than 200 patients with familial...
  • 17 December 2018
    The value of therapeutic intervention with a PCSK9 inhibitor is highly pertinent with increasingly finite resources for healthcare services. While PCSK9 inhibitors are undoubtedly extremely powerful LDL-lowering therapies that reduce cardiovascular events, their perceived cost has been a major barrier to uptake. The recent ODYSSEY OUTCOMES...
  • 17 December 2018
    Atherosclerotic cardiovascular disease is the leading cause of morbidity and mortality in patients with type 2 diabetes. Management is multifactorial, targeting major modifiable risk factors including glycaemia, dyslipidaemia, obesity and hypertension. Despite this, less than 10% of patients achieve combined target goals. To address this unmet...
  • 11 December 2018
    Reports from the 9th Closed Expert Meeting of the PCSK9 Education and Research Forum Gregory Schwartz and Michael Szarek  The post ODYSSEY OUTCOMES: Recurrent events, mortality and Lp(a) appeared first on PCSK9 Forum.
  • 03 December 2018
    Reports from the 9th Closed Expert Meeting of the PCSK9 Education and Research Forum Dr Erin Bohula  The post Is lipoprotein(a) an independent risk factor in PCSK9 inhibitor outcomes studies? appeared first on PCSK9 Forum.
  • 03 December 2018
    Reports from the 9th Closed Expert Meeting of the PCSK9 Education and Research Forum Professor Anne Tybjærg-Hansen  The post What’s new about lipoprotein(a) genetics and cardiovascular risk? appeared first on PCSK9 Forum.
  • 03 December 2018
    Reports from the 9th Closed Expert Meeting of the PCSK9 Education and Research Forum Professors Gregory Schwartz and Michael Szarek  The post Recurrent events, mortality and Lp(a) appeared first on PCSK9 Forum.
  • 15 November 2018
    The post VIDEO: Perspective on the ODYSSEY OUTCOMES Economic Study appeared first on PCSK9 Forum.
  • 15 November 2018
    The post VIDEO: New insights from ODYSSEY OUTCOMES appeared first on PCSK9 Forum.
  • 15 November 2018
    Lipoprotein(a) was a key focus. First, the 2018 US Cholesterol Guidelines incorporated elevated lipoprotein(a) as a marker of cardiovascular risk. Second, a Latebreaker session showed a favourable benefit versus risk profile for a novel antisense oligonucleotide specific to the apolipoprotein(a) component of lipoprotein(a). Now the stage is truly...
  • 13 November 2018
     The post Nicholls: Why we need to avoid recurrent events: Plaque biology considerations appeared first on PCSK9 Forum.
  • 13 November 2018
     The post Nicholls: REDUCE-IT- does the formulation matter? appeared first on PCSK9 Forum.
  • 13 November 2018
     The post Nicholls: REDUCE-IT take home messages appeared first on PCSK9 Forum.
  • 13 November 2018
     The post Rosenson: More guideline controversy appeared first on PCSK9 Forum.

Pages